Search results
Results from the WOW.Com Content Network
Tardive dyskinesia (TD) is an iatrogenic disorder that results in involuntary repetitive body movements, which may include grimacing, sticking out the tongue or smacking the lips, [1] which occurs following treatment with medication. [6] [7] Additional motor symptoms include chorea or athetosis. [1]
Ozempic is approved for type 2 diabetes, while its counterpart, Wegovy, is approved for treating obesity. Both are made by Novo Nordisk. Both are made by Novo Nordisk. ‘Yo-yo’ Weight Loss ...
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood.With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
2. Eat Smaller, More Frequent Meals. Instead of three main meals, try eating smaller, more frequent meals throughout the day. This can help if nausea is making it hard to feel like eating or if ...
The approval of Zepbound follows a series of other weight loss drugs approved to treat medical conditions other than obesity and diabetes. In March, the weight loss drug Wegovy was FDA-approved to ...
Pioglitazone, sold under the brand name Actos among others, is an anti-diabetic medication used to treat type 2 diabetes. [3] It may be used with metformin, a sulfonylurea, or insulin. [3] [4] Use is recommended together with exercise and diet. [4] It is not recommended in type 1 diabetes. [4] It is taken by mouth. [4]
Insulin glargine/lixisenatide is approved as a prescription for adults with type 2 diabetes mellitus poorly controlled by lixisenatide or basal insulin alone. [6] According to the American Diabetes Association, combination treatment of a GLP-1 receptor agonist with basal insulin should occur after HbA1C levels remain above target (7% for most type 2 people with diabetes) following use of basal ...